AIM: To determine concurrent validity of self-reported misuse of prescription opioids. DESIGN AND SETTING: Cross-sectional study in five U.S. methadone maintenance programs. PARTICIPANTS: 92 addicts. MEASUREMENTS: Self-reported questionnaire assessing past-month misuse of 14 opioid analgesics, and color photographs of five opioid analgesics with instructions to mark those used in the past month "to get high." Concordance between self-report and photograph endorsement was assessed via Kappa statistic. FINDINGS: 29 respondents completed both questionnaire and photograph endorsements. Kappas were 0.62 (OxyContin), 0.59 (methadone), 0.49 (Dilaudid), and 0.46 (generic extended-release oxycodone). CONCLUSIONS: Good-to-fair concurrent validity of self-reported abuse was seen for OxyContin, methadone, Dilaudid, and generic extended-release oxycodone.
AIM: To determine concurrent validity of self-reported misuse of prescription opioids. DESIGN AND SETTING: Cross-sectional study in five U.S. methadone maintenance programs. PARTICIPANTS: 92 addicts. MEASUREMENTS: Self-reported questionnaire assessing past-month misuse of 14 opioid analgesics, and color photographs of five opioid analgesics with instructions to mark those used in the past month "to get high." Concordance between self-report and photograph endorsement was assessed via Kappa statistic. FINDINGS: 29 respondents completed both questionnaire and photograph endorsements. Kappas were 0.62 (OxyContin), 0.59 (methadone), 0.49 (Dilaudid), and 0.46 (generic extended-release oxycodone). CONCLUSIONS: Good-to-fair concurrent validity of self-reported abuse was seen for OxyContin, methadone, Dilaudid, and generic extended-release oxycodone.
Authors: Andrew H Rogers; Brooke Y Kauffman; Jafar Bakhshaie; R Kathryn McHugh; Joseph W Ditre; Michael J Zvolensky Journal: Am J Drug Alcohol Abuse Date: 2019-03-21 Impact factor: 3.829